Who Paid My Doc
Chrystal Rhodes-Walls
Nurse Practitioner Myrtle Beach, SC Nurse Practitioner
NPI 1467628503 CMS profile 10563437
3009 Church St Ste B, Myrtle Beach, SC 29577
General payments
$2,842
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Chrystal Rhodes-Walls of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $2,842 across 184 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 86th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $493 | 29 | |
| 2022 | General | $1,070 | 72 | |
| 2021 | General | $1,279 | 83 |
Beside peers
- Chrystal Rhodes-Walls
- Nurse Practitioner median
- Middle half of Nurse Practitioner
- National median
In program year 2025, general payments to Chrystal Rhodes-Walls were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.
Show as a table
| Year | Chrystal Rhodes-Walls | Nurse Practitioner median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $50 | $22–$97 | $163 |
| 2020 | $0 | $40 | $16–$108 | $114 |
| 2021 | $1,279 | $135 | $40–$426 | $132 |
| 2022 | $1,070 | $152 | $48–$470 | $149 |
| 2023 | $493 | $166 | $54–$529 | $160 |
| 2024 | $0 | $173 | $55–$556 | $164 |
| 2025 | $0 | $174 | $55–$557 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 42 drugsPart D claims
1,774
Drug cost
$23,220
Branded share of claims
27.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Paxlovid Nirmatrelvir/Ritonavir | Brand | 31 | $5,600 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 81 | $2,015 | |
| Fluticasone Propionate | Generic | 136 | $1,473 | |
| Methylprednisolone | Generic | 237 | $1,388 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 146 | $1,353 | |
| Prednisone | Generic | 195 | $1,250 | |
| Ofloxacin | Generic | 37 | $912 | |
| Tobramycin-Dexamethasone Tobramycin/Dexamethasone | Brand | 23 | $840 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 38 | $669 | |
| Clindamycin Hcl | Generic | 69 | $619 |
The 10 drugs with the highest cost, of 42 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 97 billing codesPaid by Medicare
$82,267
Medicare patients
593
Services billed
4,229
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Arthritis | 51% | |
| Diabetes | 25% | |
| Ischemic heart disease | 22% | |
| Osteoporosis | 16% | |
| Chronic kidney disease | 15% | |
| Depression | 15% | |
| COPD | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 48 | 1,178 | $244 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 53 | 222 | $74 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 28 | 118 | $60 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 50 | 507 | $38 |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram J7644 | Office | 13 | 13 | $3 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 | Office | 14 | 26 | $1 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
184 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner in South Carolina
Related records
Nurse Practitioner in South Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner
Everyone recorded under this specialty, nationwide.
Doctors in South Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.